TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06441604
Drug: Extended-release Buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion.
Study: NCT06311916
Drug: HAIC + Tirelizumab +lenvatinib +liver resection
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
Study: NCT04994210
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects.
Study: NCT04994210
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects.
Study: NCT05718869
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03637062
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
Study: NCT05378672
Drug: Dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.
Study: NCT05760196
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
Study: NCT05505734
Drug: BDA MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
Study: NCT05505734
Drug: AS MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
Study: NCT05801783
Drug: Recombinant oncolytic herpes simplex virus type 1 (R130)
Normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT00001997
Drug: Interleukin-2, Polyethylene Glycolated
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001997
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001997
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06564298
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg iv.gtt d1, every 21 days
Study: NCT06564298
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 10mg/kg iv.gtt d1, every 21 days
Study: NCT05738057
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg on day1 of every 3 weeks, starting on day1 of cycle1
Study: NCT05738057
Drug: Gemcitabine Injection
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
Study: NCT05738057
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
Study: NCT05738057
Drug: Cisplatin-Eluting Beads
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used for D-TACE
Study: NCT06180096
Drug: Riociguat film coated tablets
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of 2.5 mg Riociguat
Study: NCT06180096
Drug: Adempas Filmtabletten
Normalized name: Adempas
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of 2.5 mg Riociguat
Study: NCT00548301
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05471648
Drug: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
Normalized name: pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
Study: NCT05471648
Drug: Perjeta (EU origin) 420 mg in 14 mL Injection
Normalized name: pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
Study: NCT05471648
Drug: Perjeta (US origin) 420 mg in 14 mL Injection
Normalized name: pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
Study: NCT05872269
Drug: Saroglitazar
Normalized name: Saroglitazar
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Mg Oral Tablet
Study: NCT05385263
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
Study: NCT05602649
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis will be orally ingested
Study: NCT05013320
Drug: Glycopyrrolate + dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
Study: NCT05013320
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine administration during the surgery.
Study: NCT04774627
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients treated at least with 1 PARPi
Study: NCT05045443
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
Study: NCT05885646
Drug: Sulthiame
Normalized name: Sulthiame
DrugBank: Sulthiame (DB08329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
Study: NCT06576635
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle
Study: NCT06576635
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle
Study: NCT06576635
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)
Study: NCT06576635
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle
Study: NCT06576635
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle
Study: NCT04594772
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
Study: NCT06436911
Drug: COVIGENIX VAX- 002
Normalized name: Vaxelis
DrugBank: Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (DB10342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENTVAX-001-01
Study: NCT05222932
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PDL1 antibody
Study: NCT04744649
Drug: JS001+XELOX or SOX
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study: NCT05225610
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
Study: NCT04704518
Drug: Sodium Hyaluronate Ophthalmic 0.4%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
Study: NCT04704518
Drug: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ophthalmic administration of one drop of Thealoz® Duo QID.
Study: NCT05087264
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
Study: NCT04687137
Drug: TAK-743 300 mg
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
Study: NCT05106335
Drug: camrelizumab + famitinib
Normalized name: Axitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: camrelizumab for intravenous injection; famitinib malate capsules for oral administration
Study: NCT05106335
Drug: famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: famitinib malate capsules for oral administration
Study: NCT06393309
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
Study: NCT06393309
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with idiopathic generalized epilepsy who were under treatment with valproate
Study: NCT05106335
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel for intravenous injection
Study: NCT06162949
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
Study: NCT06162949
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibiotic of penicillins antibiotic group
Study: NCT06162949
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An acid suppressor therapy that blocks the proton pump.
Study: NCT05740566
Drug: Tarlatamab
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab will be administered as an IV infusion.
Study: NCT05740566
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin will be administered per local SOC.
Study: NCT05740566
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan will be administered per local SOC.
Study: NCT05740566
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin will be administered per local SOC.
Study: NCT05669417
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
Study: NCT05992142
Drug: 5-ASA
Normalized name: 5-ASA
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit
Study: NCT06449430
Drug: Sedation with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation with propofol
Study: NCT06449430
Drug: Spinal analgesia with bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal analgesia with bupivacaine
Study: NCT05047211
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet 325 milligrams three times a day
Study: NCT05047211
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous infusion
Study: NCT05702931
Drug: Semaglutide 14 MG [Rybelsus]
Normalized name: semaglutide 14 MG [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
Study: NCT06369454
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
Study: NCT04854512
Drug: Metformin DR
Normalized name: DR-01
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delay-Release Metformin
Study: NCT04854512
Drug: Metformin IR
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate Release Metformin
Study: NCT04854512
Drug: Metformin DR Placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin DR Placebo
Study: NCT04854512
Drug: Metformin IR placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin IR placebo
Study: NCT05629780
Drug: Resuscitation fluid
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cristalloid fluids given as a resuscitational intervention
Study: NCT04431193
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
Study: NCT06578676
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PO, QD
Study: NCT06148792
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral treatment
Study: NCT06148792
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral treatment
Study: NCT05944744
Drug: Adenosylcobalamin
Normalized name: Adenosylcobalamin
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
Study: NCT05314127
Drug: Tazarotene 0.1% Gel,Top
Normalized name: TAZAROTENE 0.1% GEL,TOP
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily topical application at night with a cotton tipped applicator on every lesion
Study: NCT05314127
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
Study: NCT05314127
Drug: Petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied once daily at night
Study: NCT05154669
Drug: Nicotine Replacement Therapy Agent - Patches
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
Study: NCT05154669
Drug: Nicotine Replacement Therapy Agent - Lozenges
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated
Study: NCT05154669
Drug: Nicotine Replacement Therapy Agent - Gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
Study: NCT06014190
Drug: HS-20089
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
Study: NCT06362915
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
Study: NCT06362915
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist